XSTOIMPsdba
Market cap198mUSD
Dec 20, Last price
36.45SEK
1D
-0.14%
1Q
-15.72%
IPO
-62.42%
Name
Implantica AG
Chart & Performance
P/E
—
P/S
134.99
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
139.50%
Revenues
1m
+67.22%
Net income
-24m
L+14.02%
CFO
-20m
L+24.75%
Profile
Implantica AG, a medtech company, researches, develops, and sells medical implants for unmet medical needs in Switzerland. Its lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. The company also develops e-InVivo, a sensor implant to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, it develops UriControl, a remote controlled implant to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and MS patients to urinate on demand using the wireless platform. The company was founded in 2015 and is based in Vaduz, Liechtenstein. Implantica AG is a subsidiary of Implantica MediSwiss.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 1,408 67.22% | 842 117.57% | 387 154.61% | ||||
Cost of revenue | 24,508 | 20,516 | 14,755 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (23,100) | (19,674) | (14,368) | ||||
NOPBT Margin | |||||||
Operating Taxes | 74 | 39 | 22 | ||||
Tax Rate | |||||||
NOPAT | (23,174) | (19,713) | (14,390) | ||||
Net income | (23,744) 14.02% | (20,824) 35.56% | (15,361) 49.47% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (59) | ||||||
BB yield | 0.00% | ||||||
| Debt | |||||||
Debt current | 314 | ||||||
Long-term debt | 1,482 | 1,962 | 92 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 575 | 267 | |||||
Net debt | (86,126) | (106,989) | (132,644) | ||||
| Cash flow | |||||||
Cash from operating activities | (19,908) | (15,958) | (11,472) | ||||
CAPEX | (87) | (61) | (164) | ||||
Cash from investing activities | (3,154) | 41,086 | (51,609) | ||||
Cash from financing activities | (431) | (937) | 48,051 | ||||
FCF | (22,950) | (20,760) | (14,427) | ||||
| Balance | |||||||
Cash | 87,922 | 108,951 | 132,736 | ||||
Long term investments | |||||||
Excess cash | 87,852 | 108,909 | 132,717 | ||||
Stockholders' equity | 125,048 | 144,087 | 159,688 | ||||
Invested Capital | 38,667 | 36,262 | 27,200 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 283,091 | 283,112 | 281,550 | ||||
Price | 23.90 -39.87% | 39.75 -38.85% | 65.00 -58.63% | ||||
Market cap | 6,765,865 -39.88% | 11,253,684 -38.51% | 18,300,750 -55.80% | ||||
EV | 6,677,514 | 11,145,228 | 18,167,175 | ||||
EBITDA | (21,476) | (19,222) | (14,217) | ||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||